Trilaciclib dihydrochloride dihydrate is used to reduce the risk of chemotherapy-induced myelosuppression in patients with extensive-stage small cell lung cancer (ES-SCLC). It functions as a CDK4/6 inhibitor, temporarily arresting bone marrow cells in the G1 phase to protect them from chemotherapy damage. This helps decrease the incidence of neutropenia, anemia, and thrombocytopenia during chemotherapy treatment. It is grouped under the following drug class(es): CDK4/6 Inhibitors. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include G1T28 dihydrochloride dihydrate and Cosela dihydrochloride dihydrate. Its PubChem CID is 155491232.
Trilaciclib dihydrochloride dihydrate
| CAS No | 2519335-12-5 |
|---|---|
| Molecular Formula | C24H36Cl2N8O3 |
| Molecular Weight | 555.5 g/mol |
| Synonyms | 4-[[5-(4-methylpiperazin-1-yl)-2-pyridinyl]amino]spiro[1,3,5,11-tetrazatricyclo[7.4.0.02,7]trideca-2,4,6,8-tetraene-13,1′-cyclohexane]-10-one;dihydrate;dihydrochloride |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Trilaciclib dihydrochloride dihydrate is used to reduce the risk of chemotherapy-induced myelosuppression in patients with extensive-stage small cell lung cancer (ES-SCLC).
The listed CAS number is 2519335-12-5.
The listed molecular formula is C24H36Cl2N8O3.
The listed molecular weight is 555.5 g/mol.
4-[[5-(4-methylpiperazin-1-yl)-2-pyridinyl]amino]spiro[1,3,5,11-tetrazatricyclo[7.4.0.02,7]trideca-2,4,6,8-tetraene-13,1′-cyclohexane]-10-one;dihydrate;dihydrochloride.
The source lists G1T28 dihydrochloride dihydrate and Cosela dihydrochloride dihydrate.